Click on image to view larger version.
Figure 3 Transplantation of hESC-CMs in the Infarcted Heart
(A) Identification of the grafted hESC-CMs at the scars center using antienhanced green fluorescent protein (green, left) and antisarcomeric
-actinin (red, middle) antibodies. (Right) Superposition of both images. The scar was identified using anticollagen antibodies (blue) (bar: 80 µm). (B) Immunostainings of the transplanted hESC-CMs at the infarct border zone using antienhanced green fluorescent protein (green) and antitroponin I (red, right) antibodies (bar: 75 µm). (C) Identification of the grafted hESC-CMs with antihuman-human leukocyte antigen antibodies. (Top) Immunohistochemistry results (bar: 100 µm). (Bottom) Immunofluorescent staining using antihuman-human leukocyte antigen (green) and antitroponin I (red) antibodies (bar: 75 µm). (D) Development of gap junctions (Cx43 immunostaining, white) between the grafted cells (prelabeled with Vybrant-CFDA) (green, left) and host cardiomyocytes (arrows). Cardiomyocytes were identified using antitroponin I antibodies (red, middle) (bar: 60 µm). Abbreviations as in Figure 2.